NASD · Healthcare · Diagnostics & Research · USA
GeneDx Holdings Corp is a mid cap company (market value between $2 billion and $10 billion) in the Diagnostics & Research industry.
GeneDx Holdings Corp provides exome and genome sequencing tests for diagnosing genetic diseases, particularly rare pediatric disorders. The company operates a proprietary dataset called GeneDx Infinity and offers ExomeDx and GenomeDx tests to clinicians. Its customers include geneticists, pediatric specialists, and general pediatricians in hospital and outpatient settings.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the GeneDx Holdings Corp stock.
Slightly overvalued: intrinsic value $62.15 per share, market price $68.74, margin of safety -10.6% (as of 2026-10-20).
A 4.0x revenue multiple, discounted for its losses, values the shares at $62.15; the price of $68.74 is 11% above that value.
Leak Score: 23/100 on 8 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 44 Diagnostics & Research stocks
WGS is slightly overvalued (as of the 2026-10-20 close). A 4.0x revenue multiple, discounted for its losses, values the shares at $62.15; the price of $68.74 is 11% above that value.
$62.15 per share (as of the 2026-10-20 close), against a market price of $68.74. That is a margin of safety of -10.6%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
23 out of 100, which we rate "On Watch", on 8 of 12 value investing signals.